Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Gedeon Richter
Deal Size : $19.5 million
Deal Type : Agreement
Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab
Details : Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $3.0 million
April 29, 2020
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Gedeon Richter
Deal Size : $19.5 million
Deal Type : Agreement
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Hummingbird Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
Details : Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 20, 2020
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Hummingbird Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
